Fludarabine
Peroxisomal Disorders
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Peroxisomal Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Romidepsin Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
CHOLALIC ACID Mirum Pharmaceuticals, Inc. | Phase 3 | B |
Cald Hr-D Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →